IP Library › Granted Patent US 12,453,697
Granted Patent B2
US 12,453,697 · App. 17/290,708 · Granted Oct 28, 2025

Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

Inventors: Seth Wardell (Tampa, FL); Maritza Lienlaf Moreno (Tampa, FL)
Assignee: Iovance Biotherapeutics, Inc.
A61K9/0019A61K38/2013A61K40/11A61K40/42A61P35/00C12N5/0638C07K16/2809C12N2501/2302C12N2502/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,453,697
App. No.
17/290,708
Granted
Oct 28, 2025
Kind
B2
Abstract

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

Claims (27)

1. A method for expanding tumor infiltrating lymphocytes (TILs) into a therapeutic population of TILs comprising:

(a) adding into a first closed container in a closed system a plurality of tumor fragments comprising a first population of TILs obtained by processing a sample of tumor tissue resected from a subject with cancer into the plurality of tumor fragments;

(b) performing a priming first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2, optionally OKT-3, and optionally antigen presenting cells (APCs) to produce a second population of TILs, wherein the priming first expansion is performed in the first closed container comprising a first gas-permeable surface area, wherein the priming first expansion is performed for a first period of about 3 to 7 or 8 days to obtain the second population of TILs, wherein the second population of TILs is greater in number than the first population of TILs;

(c) performing a rapid second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and APCs, to produce a third population of TILs, optionally wherein the number of APCs added in the rapid second expansion is at least twice the number of APCs added in step (b), wherein the rapid second expansion is performed for a second period of about 7 to 11 days to obtain the third population of TILs, wherein the third population of TILs is a therapeutic population of TILs, wherein the rapid second expansion is performed in a second closed container comprising a second gas-permeable surface area;

(d) harvesting the therapeutic population of TILs obtained from step (c); and

(e) transferring the harvested TIL population from step (d) to an infusion bag.

2. The method of claim 1 , wherein the step of the priming first expansion comprises culturing the first population of TILs in a cell culture medium comprising IL-2, APCs, and optionally OKT-3 to produce the second population of TILs, wherein a ratio of the number of APCs in the rapid second expansion to the number of APCs in the priming first expansion is in a range of from about 2:1 to about 20:1, from about 2:1 to about 5:1, from about 2:1 to about 3:1, or from about 2:1 to about 10:1.

3. The method of claim 1 , wherein the step of the priming first expansion comprises culturing the first population of TILs in a cell culture medium comprising IL-2, APCs, and optionally OKT-3 to produce the second population of TILs, wherein a ratio of the number of APCs in the rapid second expansion to the number of APCs in the priming first expansion is about 2:1.

4. The method of claim 1 , wherein the step of the priming first expansion comprises culturing the first population of TILs in a cell culture medium comprising IL-2, APCs, and optionally OKT-3 to produce the second population of TILs, wherein the number of APCs per unit gas-permeable surface area in the priming first expansion is in a range of about 1.0×10 6 APCs/cm 2 to about 4.5×10 6 APCs/cm 2 , and wherein the number of APCs per unit gas-permeable surface area in the rapid second expansion is in a range of about 2.5×10 6 APCs/cm 2 to about 7.5×10 6 APCs/cm 2 ; or wherein the number of APCs per unit gas-permeable surface area in the priming first expansion is in a range of about 1.5×10 6 APCs/cm 2 to about 3.5×10 6 APCs/cm 2 , or about 2.0×10 6 APCs/cm 2 to about 3.0×10 6 APCs/cm 2 , and wherein the number of APCs per unit gas-permeable surface area in the rapid second expansion is in a range of about 3.5×10 6 APCs/cm 2 to about 6.0×10 6 APCs/cm 2 , or about 4.0×10 6 APCs/cm 2 to about 5.5×10 6 APCs/cm 2 ; or wherein the number of APCs in the first closed container in the priming first expansion is in a range of about 1×10 8 APCs to about 3.5×10 8 APCs, or about 1.5×10 8 APCs to about 3×10 8 APCs, or about 2×10 8 APCs to about 2.5×10 8 APCs, and wherein the number of APCs in the second closed container in the rapid second expansion is in a range of about 3.5×10 8 APCs to about 1×10 9 APCs, or about 4×10 8 APCs to about 7.5×10 8 APCs, or about 4.5×10 8 APCs to about 5.5×10 8 APCs.

5. The method of claim 1 , wherein a total number of about 2.5×10 8 APCs are added to the priming first expansion and a total number of about 5×10 8 APCs are added to the rapid second expansion, wherein optionally the second population of TILs is at least 50-fold greater in number than the first population of TILs.

6. The method of claim 1 , wherein a ratio of the number of TILs in the second population of TILs to the number of TILs in the first population of TILs is about 1.5:1 to about 100:1, about 50:1, about 25:1, about 20:1 or about 10:1.

7. The method of claim 1 , wherein after 2 to 3 days in the step of the rapid second expansion, the cell culture medium is supplemented with additional IL-2, optionally wherein the method further comprises cryopreserving the harvested TIL population in the step of harvesting the therapeutic population of TILs using a cryopreservation process.

8. The method according to claim 1 , further comprising a step of cryopreserving the infusion bag.

9. The method according to claim 8 , wherein the step of cryopreserving the infusion bag is performed using a 1:1 ratio of harvested TIL population to cryopreservation media, optionally wherein the cryopreservation media comprises 7% to 10% DMSO.

10. The method according to claim 1 , wherein the antigen-presenting cells are peripheral blood mononuclear cells (PBMCs) or artificial antigen-presenting cells, optionally wherein the PBMCs are irradiated and allogeneic.

11. The method according to claim 1 , wherein in the step of the priming first expansion the cell culture medium comprises peripheral blood mononuclear cells (PBMCs), and wherein the total number of PBMCs added to the cell culture medium in the step of the priming first expansion is about 2.5×10 8 PBMCs and/or wherein in the step of the rapid second expansion the APCs in the cell culture medium are PBMCs, and wherein the total number of PBMCs added to the cell culture medium in the step of the rapid second expansion is about 5×10 8 .

12. The method according to claim 1 , wherein the plurality of tumor fragments comprise about 60 fragments per container in the step of the priming first expansion, wherein each fragment has a volume of about 27 mm 3 , optionally wherein the multiple fragments comprise about 30 to about 60 fragments with a total volume of about 1300 mm 3 to about 1500 mm 3 or the multiple fragments comprise about 50 fragments with a total volume of about 1350 mm 3 , optionally wherein the multiple fragments comprise about 50 fragments with a total mass of about 1 gram to about 1.5 grams.

13. The method according to claim 1 , wherein the IL-2 concentration in the priming first expansion, or the rapid second expansion, is about 10,000 IU/mL to about 5,000 IU/mL, or about 6,000 IU/mL.

14. The method according to claim 1 , wherein the priming first expansion is performed within a period of 5 days, 6 days, or 7 days.

15. The method according to claim 1 , wherein the rapid second expansion is performed within a period of 7 days, 8 days, or 9 days.

16. The method according to claim 1 , wherein the priming first expansion and the rapid second expansion are each individually performed within a period of 7 days.

17. The method according to claim 1 , wherein steps of the priming first expansion through the harvesting of the therapeutic population of TILs are performed within a period of about 14 days to about 16 days, about 15 days to about 16 days, about 14 days, about 15 days, or about 16 days.

18. The method according to claim 1 , further comprising a step of cryopreserving the harvested therapeutic population of TILs using a cryopreservation process, wherein steps of the priming first expansion through the harvesting of the therapeutic population of TILs and cryopreservation are performed within a period of about 14 days to about 16 days.

19. The method according to claim 1 , wherein the therapeutic population of TILs harvested in the step of harvesting of the therapeutic population of TILs comprises sufficient TILs for a therapeutically effective dosage of the TILs, wherein optionally the number of TILs sufficient for a therapeutically effective dosage is from about 2.3×10 10 TILs to about 13.7×10 10 TILs, from about 7.5×10 9 TILs to about 100×10 9 TILs, or from about 1×10 9 TILs to about 1×10 11 TILs.

20. The method of claim 1 , wherein the third population of TILs in the step of the rapid second expansion provides for increased efficacy, increased interferon-gamma production, and/or increased polyclonality, compared to the first and/or second population of TILs.

21. The method of claim 1 , wherein the third population of TILs in the step of the rapid second expansion provides for at least a one-fold to five-fold or more interferon-gamma production as compared to TILs prepared by a process longer than 18 days.

22. The method of claim 1 , wherein effector T cells and/or central memory T cells obtained from the third population of TILs in the step of the rapid second expansion exhibit increased CD8 and CD28 expression relative to effector T cells and/or central memory T cells obtained from the second population of TILs in the step of the priming first expansion.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2025
From: WARDELL, SETH; MORENO, MARITZA LIENLAF
To: IOVANCE BIOTHERAPEUTICS, INC.
Reel/Frame 069862/0951 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2024
From: WARDELL, SETH; MORENO, MARITZA LIENLAF
To: IOVANCE BIOTHERAPEUTICS, INC.
Reel/Frame 069412/0854 →
Continuity (3)
Provisional Application 62903585 · Sep 20, 2019
Provisional Application 62755954 · Nov 5, 2018
Related Publication 20220090018A1 · Mar 24, 2022
References Cited (400)
US 4766106A · Katre et al. · 1988 [cited by applicant]
US 4897355A · Eppstein et al. · 1990 [cited by applicant]
US 4902502A · Nitecki et al. · 1990 [cited by applicant]
US 5019034A · Weaver et al. · 1991 [cited by applicant]
US 5089261A · Nitecki et al. · 1992 [cited by applicant]
US 5126132A · Rosenberg · 1992 [cited by applicant]
US 5128257A · Baer · 1992 [cited by applicant]
US 5137817A · Busta et al. · 1992 [cited by applicant]
US 5173158A · Schmukler · 1992 [cited by applicant]
US 5206344A · Katre et al. · 1993 [cited by applicant]
US 5232856A · Firth · 1993 [cited by applicant]
US 5273525A · Hofmann · 1993 [cited by applicant]
US 5279833A · Rose · 1994 [cited by applicant]
US 5304120A · Crandell et al. · 1994 [cited by applicant]
US 5318514A · Hofmann · 1994 [cited by applicant]
US 5443983A · Ochoa et al. · 1995 [cited by applicant]
US 5593875A · Wurm et al. · 1997 [cited by applicant]
US 5766902A · Craig et al. · 1998 [cited by applicant]
US 5849902A · Arrow et al. · 1998 [cited by applicant]
US 5908635A · Thierry · 1999 [cited by applicant]
US 5928893A · Kang et al. · 1999 [cited by applicant]
US 6010613A · Walters et al. · 2000 [cited by applicant]
US 6025337A · Truong et al. · 2000 [cited by applicant]
US 6056938A · Unger et al. · 2000 [cited by applicant]
US 6078490A · Walters · 2000 [cited by applicant]
US 6110490A · Thierry · 2000 [cited by applicant]
US 6210669B1 · Aruffo et al. · 2001 [cited by applicant]
US 6303121B1 · Kwon · 2001 [cited by applicant]
US 6352694B1 · June et al. · 2002 [cited by applicant]
US 6362325B1 · Kwon · 2002 [cited by applicant]
US 6410517B1 · Truong et al. · 2002 [cited by applicant]
US 6475994B2 · Tomalia et al. · 2002 [cited by applicant]
US 6479626B1 · Kim et al. · 2002 [cited by applicant]
US 6489458B2 · Hackett et al. · 2002 [cited by applicant]
US 6534055B1 · June et al. · 2003 [cited by applicant]
US 6534261B1 · Cox, III et al. · 2003 [cited by applicant]
US 6534484B1 · Wheeler et al. · 2003 [cited by applicant]
US 6569997B1 · Kwon · 2003 [cited by applicant]
US 6607882B1 · Cox, III et al. · 2003 [cited by applicant]
US 6627442B1 · Humeau et al. · 2003 [cited by applicant]
US 6706289B2 · Lewis et al. · 2004 [cited by applicant]
US 6746838B1 · Choo et al. · 2004 [cited by applicant]
US 6794136B1 · Eisenberg et al. · 2004 [cited by applicant]
US 6824978B1 · Cox, III et al. · 2004 [cited by applicant]
US 6866997B1 · Choo et al. · 2005 [cited by applicant]
US 6867041B2 · Berenson et al. · 2005 [cited by applicant]
US 6887466B2 · June et al. · 2005 [cited by applicant]
US 6887673B2 · Kunkel et al. · 2005 [cited by applicant]
US 6903185B2 · Kim et al. · 2005 [cited by applicant]
US 6905680B2 · June et al. · 2005 [cited by applicant]
US 6905681B1 · June et al. · 2005 [cited by applicant]
US 6905685B2 · Kwon · 2005 [cited by applicant]
US 6933113B2 · Case et al. · 2005 [cited by applicant]
US 6974863B2 · Kwon · 2005 [cited by applicant]
US 6979539B2 · Cox, III et al. · 2005 [cited by applicant]
US 7013219B2 · Case et al. · 2006 [cited by applicant]
US 7030215B2 · Liu et al. · 2006 [cited by applicant]
US 7144575B2 · June et al. · 2006 [cited by applicant]
US 7175843B2 · June et al. · 2007 [cited by applicant]
US 7189705B2 · Lam et al. · 2007 [cited by applicant]
US 7220719B2 · Case et al. · 2007 [cited by applicant]
US 7232566B2 · June et al. · 2007 [cited by applicant]
US 7241573B2 · Choo et al. · 2007 [cited by applicant]
US 7241574B2 · Choo et al. · 2007 [cited by applicant]
US 7288638B2 · Jure-Kunkel et al. · 2007 [cited by applicant]
US 7479269B2 · June et al. · 2009 [cited by applicant]
US 7504101B2 · Weinberg · 2009 [cited by applicant]
US 7550140B2 · Bakker et al. · 2009 [cited by applicant]
US 7572631B2 · Berenson et al. · 2009 [cited by applicant]
US 7585849B2 · Liu et al. · 2009 [cited by applicant]
US 7595376B2 · Kim et al. · 2009 [cited by applicant]
US 7622444B2 · Weinberg · 2009 [cited by applicant]
US 7687070B2 · Gebeyehu et al. · 2010 [cited by applicant]
US 7696175B2 · Epstein et al. · 2010 [cited by applicant]
US 7943743B2 · Korman et al. · 2011 [cited by applicant]
US 7951365B2 · Winqvist et al. · 2011 [cited by applicant]
US 7960515B2 · Min et al. · 2011 [cited by applicant]
US 7961515B2 · Kato et al. · 2011 [cited by applicant]
US 8007785B2 · Winqvist et al. · 2011 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8034334B2 · Dudley et al. · 2011 [cited by applicant]
US 8133983B2 · Bakker et al. · 2012 [cited by applicant]
US 8206702B2 · Winqvist et al. · 2012 [cited by applicant]
US 8211424B2 · Winqvist et al. · 2012 [cited by applicant]
US 8211425B2 · Winqvist et al. · 2012 [cited by applicant]
US 8236930B2 · Min et al. · 2012 [cited by applicant]
US 8287857B2 · Dudley et al. · 2012 [cited by applicant]
US 8337850B2 · Ahrens et al. · 2012 [cited by applicant]
US 8383099B2 · Dudley et al. · 2013 [cited by applicant]
US 8450460B2 · Hill et al. · 2013 [cited by applicant]
US 8586526B2 · Gregory et al. · 2013 [cited by applicant]
US 8617884B2 · Berenson et al. · 2013 [cited by applicant]
US 8697359B1 · Zhang · 2014 [cited by applicant]
US 8771945B1 · Zhang · 2014 [cited by applicant]
US 8795965B2 · Zhang · 2014 [cited by applicant]
US 8809050B2 · Vera et al. · 2014 [cited by applicant]
US 8821867B2 · Ahrens et al. · 2014 [cited by applicant]
US 8865406B2 · Zhang et al. · 2014 [cited by applicant]
US 8871445B2 · Cong et al. · 2014 [cited by applicant]
US 8889356B2 · Zhang · 2014 [cited by applicant]
US 8895308B1 · Zhang et al. · 2014 [cited by applicant]
US 8906616B2 · Zhang et al. · 2014 [cited by applicant]
US 8921519B2 · Hill et al. · 2014 [cited by applicant]
US 8932814B2 · Cong et al. · 2015 [cited by applicant]
US 8945839B2 · Zhang · 2015 [cited by applicant]
US 8956860B2 · Vera et al. · 2015 [cited by applicant]
US 8993233B2 · Zhang et al. · 2015 [cited by applicant]
US 8999641B2 · Zhang et al. · 2015 [cited by applicant]
US 9006399B2 · Liu et al. · 2015 [cited by applicant]
US 9028824B2 · Min et al. · 2015 [cited by applicant]
US 9074185B2 · Dudley et al. · 2015 [cited by applicant]
US 9080171B2 · Khvorova et al. · 2015 [cited by applicant]
US 9163085B2 · Liu et al. · 2015 [cited by applicant]
US 9340599B2 · Hill et al. · 2016 [cited by applicant]
US 9359420B2 · Hill et al. · 2016 [cited by applicant]
US 9468678B2 · Ahrens et al. · 2016 [cited by applicant]
US 9476028B2 · Karlsson-Parra et al. · 2016 [cited by applicant]
US 9528088B2 · Berenson et al. · 2016 [cited by applicant]
US 9687510B2 · Borrello et al. · 2017 [cited by applicant]
US 9790490B2 · Zhang et al. · 2017 [cited by applicant]
US 9844569B2 · Gros et al. · 2017 [cited by applicant]
US 9914783B1 · Afar et al. · 2018 [cited by applicant]
US 10130659B2 · Wardell · 2018 [cited by applicant]
US 10363273B2 · Wardell · 2019 [cited by applicant]
US 10517894B2 · Frank · 2019 [cited by applicant]
US 10537595B2 · Wardell · 2020 [cited by applicant]
US 10653723B1 · Wardell · 2020 [cited by applicant]
US 10905718B2 · Wardell · 2021 [cited by applicant]
US 10918666B2 · Wardell · 2021 [cited by applicant]
US 10933094B2 · Wardell · 2021 [cited by applicant]
US 10946044B2 · Wardell · 2021 [cited by applicant]
US 10946045B2 · Wardell · 2021 [cited by applicant]
US 10953046B2 · Wardell · 2021 [cited by applicant]
US 10953047B2 · Wardell · 2021 [cited by applicant]
US 11013770B1 · Wardell · 2021 [cited by applicant]
US 11026974B2 · Frank · 2021 [cited by applicant]
US 11168303B2 · Wardell · 2021 [cited by applicant]
US 11168304B2 · Wardell · 2021 [cited by applicant]
US 11220670B2 · Simpson-Abelson · 2022 [cited by applicant]
US 11254913B1 · Wardell · 2022 [cited by applicant]
US 11293009B2 · Simpson-Abelson · 2022 [cited by applicant]
US 11351198B2 · Frank · 2022 [cited by applicant]
US 11357841B2 · Ritthipichai · 2022 [cited by applicant]
US 11401503B2 · Rosenberg · 2022 [cited by examiner]
US 11401507B2 · Simpson-Abelson · 2022 [cited by applicant]
US 11433097B2 · Fardis · 2022 [cited by applicant]
US 11517592B1 · Wardell · 2022 [cited by applicant]
US 11529372B1 · Wardell · 2022 [cited by applicant]
US 11541077B2 · Wardell · 2023 [cited by applicant]
US 11631483B2 · Brooks · 2023 [cited by applicant]
US 11713446B2 · Chartier-Courtaud · 2023 [cited by applicant]
US 11819517B2 · Wardell · 2023 [cited by applicant]
US 20050095244A1 · Jure-Kunkel et al. · 2005 [cited by applicant]
US 20050106717A1 · Wilson et al. · 2005 [cited by applicant]
US 20100136030A1 · Salah-Eddine et al. · 2010 [cited by applicant]
US 20110027218A1 · Hill et al. · 2011 [cited by applicant]
US 20110039914A1 · Pavco et al. · 2011 [cited by applicant]
US 20110052530A1 · Dudley et al. · 2011 [cited by applicant]
US 20110111494A1 · Hill et al. · 2011 [cited by applicant]
US 20110136228A1 · Vera et al. · 2011 [cited by applicant]
US 20110201118A1 · Yang et al. · 2011 [cited by applicant]
US 20120244133A1 · Rosenberg et al. · 2012 [cited by applicant]
US 20130102075A1 · Vera et al. · 2013 [cited by applicant]
US 20130115617A1 · Wilson · 2013 [cited by applicant]
US 20130117869A1 · Duchateau et al. · 2013 [cited by applicant]
US 20130131141A1 · Khvorova et al. · 2013 [cited by applicant]
US 20130131142A1 · Libertine et al. · 2013 [cited by applicant]
US 20130315884A1 · Galetto · 2013 [cited by applicant]
US 20140227237A1 · June et al. · 2014 [cited by applicant]
US 20140328791A1 · Bossard et al. · 2014 [cited by applicant]
US 20140377284A1 · Simons et al. · 2014 [cited by applicant]
US 20140377739A1 · Welch et al. · 2014 [cited by applicant]
US 20150110734A1 · Hill et al. · 2015 [cited by applicant]
US 20150126709A1 · Hill et al. · 2015 [cited by applicant]
US 20150126710A1 · Hill et al. · 2015 [cited by applicant]
US 20150132288A1 · Simons et al. · 2015 [cited by applicant]
US 20150175966A1 · Vera et al. · 2015 [cited by applicant]
US 20150190506A1 · Cheung et al. · 2015 [cited by applicant]
US 20150203871A1 · Juillerat et al. · 2015 [cited by applicant]
US 20150320798A1 · Borrello et al. · 2015 [cited by applicant]
US 20160010058A1 · Gros et al. · 2016 [cited by applicant]
US 20160120906A1 · Galetto et al. · 2016 [cited by applicant]
US 20160208216A1 · Vera et al. · 2016 [cited by applicant]
US 20160215262A1 · Powell · 2016 [cited by applicant]
US 20160304873A1 · Wolfson et al. · 2016 [cited by applicant]
US 20170044496A1 · Sarnaik et al. · 2017 [cited by applicant]
US 20170081635A1 · Sarnaik et al. · 2017 [cited by applicant]
US 20170107490A1 · Maeurer · 2017 [cited by applicant]
US 20170114321A1 · Berenson et al. · 2017 [cited by applicant]
US 20170152478A1 · Rosenberg et al. · 2017 [cited by applicant]
US 20170258838A1 · Borrello et al. · 2017 [cited by applicant]
US 20180127715A1 · Veerapathran et al. · 2018 [cited by applicant]
US 20180148690A1 · Gros et al. · 2018 [cited by applicant]
US 20180187150A1 · De Larichaudy · 2018 [cited by applicant]
US 20180207201A1 · Wardell et al. · 2018 [cited by applicant]
US 20180228841A1 · Frank et al. · 2018 [cited by applicant]
US 20180280436A1 · Wardell et al. · 2018 [cited by applicant]
US 20190000070A1 · De Larichaudy et al. · 2019 [cited by applicant]
US 20190062706A1 · Almaasbak et al. · 2019 [cited by applicant]
US 20190136186A1 · Germeroth et al. · 2019 [cited by applicant]
CN 102816734A · 2012 [cited by applicant]
CN 106244538A · 2016 [cited by applicant]
CN 106591232A · 2017 [cited by applicant]
CN 107384867A · 2017 [cited by applicant]
EP 0672141B1 · 2003 [cited by applicant]
EP 1539929B1 · 2013 [cited by applicant]
EP 2925329A1 · 2015 [cited by applicant]
EP 3188740A1 · 2017 [cited by applicant]
EP 3365434A1 · 2018 [cited by applicant]
EP 3368659A1 · 2018 [cited by applicant]
EP 3487990A1 · 2019 [cited by applicant]
TW 201839129A · 2018 [cited by applicant]
WO WO9014074A1 · 1990 [cited by applicant]
WO WO9116024A1 · 1991 [cited by applicant]
WO WO9117424A1 · 1991 [cited by applicant]
WO WO9512673A1 · 1995 [cited by applicant]
WO WO9521925A1 · 1995 [cited by applicant]
WO WO9813526A1 · 1998 [cited by applicant]
WO WO1998030679A1 · 1998 [cited by applicant]
WO WO2004031370A1 · 2004 [cited by applicant]
WO WO2006121810A2 · 2006 [cited by applicant]
WO WO2008025516A2 · 2008 [cited by applicant]
WO WO2009007120A2 · 2009 [cited by applicant]
WO WO2009040789A2 · 2009 [cited by applicant]
WO WO2009045457A2 · 2009 [cited by applicant]
WO WO2009102427A2 · 2009 [cited by applicant]
WO WO2010003766A2 · 2010 [cited by applicant]
WO WO2010010051A1 · 2010 [cited by applicant]
WO WO2010033246A1 · 2010 [cited by applicant]
WO WO2010033247A2 · 2010 [cited by applicant]
WO WO2010042433A1 · 2010 [cited by applicant]
WO WO2010078966A1 · 2010 [cited by applicant]
WO WO2011072088A2 · 2011 [cited by applicant]
WO WO2011119852A1 · 2011 [cited by applicant]
WO WO2011119887A1 · 2011 [cited by applicant]
WO WO2012027328A2 · 2012 [cited by applicant]
WO WO2012032433A1 · 2012 [cited by applicant]
WO WO2012065086A1 · 2012 [cited by applicant]
WO WO2012129201A1 · 2012 [cited by applicant]
WO WO2012177788A1 · 2012 [cited by applicant]
WO WO2013028231A1 · 2013 [cited by applicant]
WO WO2013038191A2 · 2013 [cited by applicant]
WO WO2013057500A1 · 2013 [cited by applicant]
WO WO2013059343A1 · 2013 [cited by applicant]
WO WO2013088147A1 · 2013 [cited by applicant]
WO WO2013173835A1 · 2013 [cited by applicant]
WO WO2013188427A1 · 2013 [cited by applicant]
WO WO2014148895A1 · 2014 [cited by applicant]
WO WO2014210036A1 · 2014 [cited by applicant]
WO WO2015009604A1 · 2015 [cited by applicant]
WO WO2015119923A1 · 2015 [cited by applicant]
WO WO2015157636A1 · 2015 [cited by applicant]
WO WO2015189357A1 · 2015 [cited by applicant]
WO WO2015188839A1 · 2015 [cited by applicant]
WO WO2015189356A1 · 2015 [cited by applicant]
WO WO2016053338A1 · 2016 [cited by applicant]
WO WO2016096903A1 · 2016 [cited by applicant]
WO WO2017008063A1 · 2017 [cited by applicant]
WO WO2017001784A1 · 2017 [cited by applicant]
WO WO2017048614A1 · 2017 [cited by applicant]
WO WO2017070151A1 · 2017 [cited by applicant]
WO WO2017123663A1 · 2017 [cited by applicant]
WO WO2018005712A1 · 2018 [cited by applicant]
WO WO2018081473A1 · 2018 [cited by applicant]
WO WO2018081789A8 · 2018 [cited by applicant]
WO WO2018102761A1 · 2018 [cited by applicant]
WO WO2018129332A1 · 2018 [cited by applicant]
WO WO2018170188A2 · 2018 [cited by applicant]
WO WO2018182817A1 · 2018 [cited by applicant]
WO WO2018209115A1 · 2018 [cited by applicant]
Rosenberg et al., Clin Cancer Res. 2011;17(13): 4550-7. (Year: 2011). [cited by examiner]
Sadeghi et al. Large-scale bioreactor expansion of tumor-infiltrating lymphocytes. J Immunological Methods. 2011; 364: 94-100. (Year: 2011). [cited by examiner]
Frank et al., Stable tumor-infiltrating lymphocytes (TIL) phenotype following cryopreservation. J ImmunoTherapy of Cancer. 2016; 4(Suppl 1):82, p. 20. (Year: 2016). [cited by examiner]
Maecker et al. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunology 2005, 6:17, p. 1-14. (Year: 2005). [cited by examiner]
Piscopo et al. Bioengineering Solutions for Manufacturing Challenges in CAR T Cells. Biotechnol. J. 2018; 13: 1700095, p. 1-10. (Year: 2018). [cited by examiner]
Chacon et al, Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. Clin Cancer Res; 2015; 21(3); 611-21. (Year: 2015). [cited by examiner]
Hopewell et al. Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process. Cytotherapy, 2019; 21: 307-314. (Year: 2019). [cited by examiner]
Besser et al., “Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients”; J Immunother 32, 415-423 (2009). [cited by applicant]
Besser, et al., “Adoptive Transfer of Tumor-Infiltrating Lymphocytes inPatients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies”; Clin Cancer Res, 19(17):0F1-0F9 (2… [cited by applicant]
Donia M, et al.. Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. Cytotherapy. Aug. 2014;16(8):1117-20. [cited by applicant]
Donia, et al., “Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour-Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution”; Scandinavian Journal of Immunology, 75… [cited by applicant]
Dudley et al., “Adoptive Cell Transfer Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients with Refractory Metastatic Melanoma”, J. Clin. Oncol. Apr. 2005, 23(10), 2346-57. [cited by applicant]
Dudley et al., “Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients,” J Immunother., 2003: 26(4): 332-342. [cited by applicant]
Dudley, et al.,“Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes”, Science, Oct. 2002, 298, 850-54. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2018/012633 dated May 25, 2018, 14 pages. [cited by applicant]
He et al., “Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy,” Chinese Journal of Cancer, vol. 31, No. 6, Jun. 5, 2012. [cited by applicant]
Jin et al., “Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permiable flasks to numbers needed for patient treatment”, J. Immunotherapy, 2012, 35:283-292. [cited by applicant]
Li et al. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol. Jan. 1, 2010;184(1):45… [cited by applicant]
Massaro A. F. et al., Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes. Cancer Res, May 1, 1990, vol. 50, No. 9, pp. 2587-2592. [cited by applicant]
Robbins, et al., “Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy”; J. Immunol 2004; 173, 7125-7130. [cited by applicant]
Rosenberg SA, Dudley ME. “Adoptive cell therapy for the treatment of patients with metastatic melanoma”, Curr Opin Immunol. Apr. 2009;21(2):233-40. [cited by applicant]
Rosenberg, “IL-2: The First Effective Immunotherapy for Human Cancer,” The Journal of Immunology, col. 192, No. 12, Jun. 6, 2014. [cited by applicant]
Sadeghi, et al., “Rapid expansion of T cells: Effects of culture and cryopreservation and improtance of short-term cell recovery”, Acta Oncologica 2013, 52, 978-986. [cited by applicant]
Somerville RP, et al., “Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor”, J Transl Med. Apr. 4, 2012;10:69. [cited by applicant]
Tran et al., “Minimally Cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy”, J. Immunother., Oct. 2008; 31(8), 742-751. [cited by applicant]
Search Reported dated Feb. 2022 for Singapore Patent Application No. 11202104615V, 3 pages. [cited by applicant]
Ye, Q. et al.; “Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes”, Journal of Translational Medicine, 2011, 9:131. [cited by applicant]
Akkök, C. A. et al. “Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediator… [cited by applicant]
Andersen, Rikke et al. “Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.” Clinical cancer research : an … [cited by applicant]
Axelsson et al., “Cryopreserved peripheral blood mononuclear cells are suitable for the assessment of immunological markers in type 1 diabetic children”, Cryobiology, Aug. 2008, 57, 201-208. [cited by applicant]
Bajgain, P. et al., “Optimizing the production of suspension cells using the G-Rex “M” series”, Molecular Therapy—Methods and Clinical Development, vol. 1, Jan. 1, 2014. [cited by applicant]
Baruch et al., “Adoptive T cell therapy: An overview of obstacles and opportunities : ACT Obstacles and Opportunities”, Cancer, vol. 123, No. S11, May 19, 2017, pp. 2154-2162. [cited by applicant]
Besser, Michal J et al. “Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.” Clinical cancer research : an official jour… [cited by applicant]
Chacon et al., “Co-stimulation through 4-1BB/CD137 Improves the Expansion and Fundtion of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy”, PLOS One, vol. 8, No. 4, Apr. 1, 2013, 25 pages. [cited by applicant]
Chang C.-H. et al., “Metabolic competition in the tumor microenvironment is a driver of cancer progression”, Cell., Sep. 10, 2015, vol. 162, No. 6, pp. 1229-1241. [cited by applicant]
Chang et al., “Emerging concepts in immunotherapy T-cell metabolism as a therapeutic target”, Nat. Immunol., Apr. 2016, 17(4), 364-368. [cited by applicant]
Dudley et al., “CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma” Clin Cancer Res, 16:6122-6131 (2010). [cited by applicant]
Dudley, et al., “Adoptive Cell Therapy for Patients with Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens” , J. Clin. Oncol., Nov. 2008, 26(32), 5233-39. [cited by applicant]
Forget et al., “Activation and propagation of tumor infiltrating lymphocytes on clinical-grade designer artificial antigen presenting cells for adoptive immunotherapy of melanoma”, Journal of Immunotherapy, vol. 37 No. … [cited by applicant]
Forget, Marie-Andrée et al. “The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity.” Oncoimmunology vol. 5,… [cited by applicant]
Frank et al., “Remarkably Stable Tumor-Infiltrating Lymphocytes (TIL) for Infusion Phenotype Following Cryopreservation”, Nov. 6, 2016, Retrieved from the Internet: http://www.iovance.com/wp-content/uploads/2017/05/LION… [cited by applicant]
Garaud, Soizic et al. “A simple and rapid protocol to non-enzymatically dissociate fresh human tissues for the analysis of infiltrating lymphocytes.” Journal of visualized experiments : JoVE ,94 52392. Dec. 6, 2014, doi… [cited by applicant]
Gassner, et al., “Fludarabine modulates composition and function of the T Cell pool in patients with chronic lymphocytic leukaemia”, Cancer. Immunol. Immunother., 2011, 60, 75-85. [cited by applicant]
Gattinoni, et al., “Adoptive immunotherapy for cancer: building on success”, Nat. Rev. Immunol. May 2006, 6(5), 383-393. [cited by applicant]
Gladstone, D E et al. “Infusion of cryopreserved autologous lymphocytes using a standard peripheral i.v. catheter.” Bone marrow transplantation vol. 49,8 (2014): 1119-20. doi:10.1038/bmt.2014.98. [cited by applicant]
Glassman, A B, and C E Bennett. “Cryopreservation of human lymphocytes: a brief review and evaluation of an automated liquid nitrogen freezer.” Transfusion vol. 19,2 (1979): 178-81. doi:10.1046/j.1537-2995.1979.19279160… [cited by applicant]
Goff et al., “Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL”, J. Immunother, Oct. 2010, 33(8), 840-847. [cited by applicant]
Goff SL, et al., “Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma”, J Clin Oncol. Jul. 10, 2016;… [cited by applicant]
Hall et al., “Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors”, Journal for ImmunoTherapy of Cancer, vol. 4, No. 1, pp. 1-12. [cited by applicant]
Hasan et al., “Artificial Antigen Presenting Cells: An Off the Shelf Approach for Generation of Desirable T-Cell Populations for Broad Application of Adoptive Immunotherapy”, Adv Genet Eng, 2015, 4:3. [cited by applicant]
Henning AL,et al.. Measurement of T-Cell Telomere Length Using Amplified-Signal FISH Staining and Flow Cytometry. Curr Protoc Cytom. Jan. 5, 2017;79:7.47.1-7.47.10. doi:10.1002/cpcy.11. PubMed PMID 28055115. [cited by applicant]
Hernandez-Chacon et al., “Costimulation through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes from Activation-induced Cell Death and Enhances Antitumor Effector Function”, Journal of Imm… [cited by applicant]
Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. Jan. 2014;257(1):56-71. doi:10.1111/imr.12132. Review. PubMed PMID: 24329789; PubMed Central PMCID: PMC392… [cited by applicant]
Huang et al., “Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression”; J. Immunother, 28(3), 258-267 (2005). [cited by applicant]
Ikarashi, H et al., “Solid-phase anti-CD3 antibody activation and cryopreservation of human tumor-infiltrating lymphocytes derived from epithelial ovarian cancer”, Japanese Journal of Cancer Research, vol. 83, No. 12, D… [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2017/058610 dated Mar. 8, 2018, 13 pages. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2018/040474 dated Nov. 14, 2018, 17 pages. [cited by applicant]
Itzhaki, Orit et al. “Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy.” Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 34,2 (201… [cited by applicant]
Iyer, R.K. et al., “Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges”, Frontiers in Medicine, vol. 5, May 23, 2018. [cited by applicant]
Jin et al., “Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules”, Journal of Transactional Medicine, col. 16. No. 1, Jan. 24, 2018. [cited by applicant]
Junker, Niels et al. “Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.” Cytotherapy vol. 13,7 (2011): 822-34. doi:10.3109/14653249… [cited by applicant]
Klapper, J.A. et al., “Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy”, Journal of Immunological Methods, vol. 345, No. 1-2, Jun. 30, 2009. [cited by applicant]
Lee et al., “Tumor-Infiltrating Lymphocytes in Melanoma”, Curr Oncol Rep. Aug. 2012, 14, 468-474. [cited by applicant]
Merhavi-Shoham et al., “Adoptive Cell Therapy for Metastatic Melanoma”, Cancer Journal, vol. 23, No. 1, Jan. 1, 2017. [cited by applicant]
Mullinax et al., “Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma”, Frontiers in Oncology, vol. 8, Mar. 2, 2018. [cited by applicant]
Muranski, et al., “Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?”, Nat. Clin. Pract. Oncol., Dec. 2006, 3, 668-681. [cited by applicant]
Nguyen, Linh T et al. “Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs).” PloS one vol. 5,11 e13940. Nov. 10, 2010, doi:10.1371/journal.pone.0013940. [cited by applicant]
Riddell, et al., “Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones”, Science, Jul. 1992, 257, 238-41. [cited by applicant]
Rohaan et al., “Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option”, Journal for Immunotherapy of Cancer, vol. 6, No. 1, Oct. 3, 2018, pp. 1-16. [cited by applicant]
Rosenberg SA, et al. “Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy”, Clinical Cancer research, vol. 17, No. 13, Jul. 1, 2011 pp. 4550-4557. [cited by applicant]
Rosenberg, S A et al. “A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.” Science (New York, N.Y.) vol. 233,4770 (1986): 1318-21. doi: 10.1126/science.3489291. [cited by applicant]
Rosenberg, S A et al. “Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.” Journal of the National Cancer Institute vol. 86,15 (1994): 1159-66. doi:10.1093/j… [cited by applicant]
Rosenberg, S A et al. “Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.” The New England journal of medicine vol. 319,25 (1988): 16… [cited by applicant]
Rufer N, et al., “Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry”, Nat Biotechnol. Aug. 1998; 16(8):743-7. PubMed PMID: 9702772. [cited by applicant]
Shen X,et al.. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother. Jan. 2007;30(1):123-9. PubMed PMID:17198091; PubMed Central PMCID: PMC2151201. [cited by applicant]
Tsoukas et al., “Activation of resting T lymphocytes by anti-CD3 (T3) antibodies in the absence of monocytes”, J. Immunol. 1985, 135, 1719. [cited by applicant]
Van den Bossche, J. et al. “Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis.” Journal of visualized experiments : JoVE , 105 53424. Nov. 28, … [cited by applicant]
Wang & Riviere, “Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies”, Cancer Gene Therapy, 2015, 22: 85-94. [cited by applicant]
Wardell et al., “A cryopreserved tumor infiltrating lymphocyte (TIL) product for LN-44”, Nov. 8, 2017, retrieved from the Internet: URL: http://www.iovance.com/wp-content/uploads/2017/11/SITC2017_Seth_poster_FINAL_SWDE_… [cited by applicant]
Wilson Wolf—Superior Cell Culture Devices, G-Rex, Oct. 31, 2016. [cited by applicant]
Ye, et al., “Engineered Artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes”, J. Translat. Med. 2011, 9(131), 13 pages. [cited by applicant]
Zhou J, et al.. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. Nov. 15, 2005;175(10):7046-52. PubMed … [cited by applicant]
Zhou, et al., “Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy”; J. Immunother, 28, 53-62 (2005). [cited by applicant]
Zuliani, T. et al., “Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permiable bag: interests for adoptive immunotherapy”, Journal of Translational Medicine, vol. 9, No. 1, Ma… [cited by applicant]
Schiltz, P M et al. “Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.” Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 20,5 (1997): 377-86.… [cited by applicant]
Spiess, P J et al. “In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.” Journal of the National Cancer Institute vol. 79,5 (1987): 1067-75. [cited by applicant]
Wu, Richard et al. “Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.” Cancer journal (Sudbury, Mass.) vol. 18,2 (2012): 160-75. doi:10.1… [cited by applicant]
Meng, Qingda et al. “Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.” Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 39,2 (2016): 81-9. doi:10.1097/CJI.0000000000000111. [cited by applicant]
Peng, Weiyi et al. “PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.” Cancer research vol. 72,20 (2012): 5209-18. doi:10.1158/0008-5472.CAN-12-1187. [cited by applicant]
NCT03374839, ClinicalTrials.gov. [cited by applicant]
Katz, Steven C et al. “Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.” Clinical cancer research : an official journal of… [cited by applicant]
Grimm, E. et al., Characterization of interleukin-2-initiated versus OKT3-initiated human tumor infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype, Canc… [cited by applicant]
Rohaan, M. et al., “Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option,” Journal for Immuno Therapy of Cancer, 2018, 6:102, pp. 1-16. [cited by applicant]
Hege, K. et al., “Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer,” Journal for ImmunoTherapy of Cancer, 2017, 5:22, pp. 1-14. [cited by applicant]
OriGen Biomedical, “PermaLife Cell Culture Bags,” 2017, 2 pages. [cited by applicant]
Ahmad, Z. et al., “scFv Antibody: Principles and Clinical Application,” Clin. & Dev. Immunol., 2012, 980250, doi:10.1155/2012/980250, 15 pages. [cited by applicant]
Augustyns, K., et al., “Incorporation of hexose nucleoside analogues into oligonucleotides: synthesis, base-pairing properties and enzymatic stability,” Nucl. Acids. Res., 1992, 20(18):4711-4716. [cited by applicant]
Beane, J. et al., “Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma,” Molecular Therapy, Aug. 2015, 23(8):1380-1390. [cited by applicant]
Bergan, R. et al., “Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy,” Nucleic Acids Research, 1993, 21(15):3567-3573. [cited by applicant]
Byrne, M. et al., “Novel Hydrophobically Modified Asymmetric RNAi Compounds (sd-rxRNA) Demonstrate Robust Efficacy in the Eye,” J. Ocular Pharmacology and Therapeutics, 2013, 00:00, 1-10. [cited by applicant]
Cepko, C. et al., “Transduction of Genes Using Retrovirus Vectors,” Current Protocols in Molecular Biology, 1996, 9.9.1-9.9.16. [cited by applicant]
Chen, C. et al., “High-Efficiency Transformation of Mammalian Cells by Plasmid DNA,” Molecular and Cellular Biology, Aug. 1987, 7(8):2745-2752. [cited by applicant]
Cieri, N. et al., “IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors,” Blood, Jan. 24, 2013, 121(4):573-584. [cited by applicant]
Cox, D. et al., “Therapeutic Genome Editing: Prospects and Challenges,” Nat. Med., Feb. 2015, 21(2):121-131. [cited by applicant]
Curti, B. et al., “OX40 is a potent immune stimulating target in late stage cancer patients,” Dec. 15, 2013, Cancer Res., 73(24):7189-7198. [cited by applicant]
Damsky, W. et al., “Mouse melanoma models and cell lines,” Pigment Cell Melanoma Res., 2010, 23:853-859. [cited by applicant]
De Marco, A., “Biotechnological applications of recombinant single-domain antibody fragments,” Microbial Cell Factories, 2011, 10:44, 1-14. [cited by applicant]
Dull T. et al., “A Third-Generation Lentivirus Vector with a Conditional Packaging System,” Journal of Virology, Nov. 1998, 72(11):8463-8471. [cited by applicant]
Eton, O. et al., “A Phase II Study of ‘Decrescendo’ Interleukin-2 plus Interferon-α-2a in Patients with Progressive Metastatic Melanoma after Chemotherapy,” Cancer, Apr. 1, 2000, 88(7):1703-1709. [cited by applicant]
Fantozzi, A. et al., “Mouse models of breast cancer metastasis,” Breast Cancer Research, 2006, 8:212, pp. 1-11. [cited by applicant]
FDA, “Guidance, Compliance & Regulatory Information (Biologics),” https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics, 4 pages. [cited by applicant]
FDA, “Tissue Guidances,” http://www.fda.gov/cber/guidelines.htm, 3 pages. [cited by applicant]
Felgner, P. et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,” Proc. Natl. Acad. Sci. USA, Nov. 1987, 84:7413-7417. [cited by applicant]
Fisher, T. et al., “Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity,” Cancer Immunolog. & Immunother., 2012, 61:1721- 1733. [cited by applicant]
Fong, M. et al., “Ovarian cancer mouse models: a summary of current models and their limitations,” Journal of Ovarian Research, 2009, 2:12, pp. 1-8. [cited by applicant]
Fry, T. et al., “Interleukin-7: from bench to clinic,” Blood, Jun. 1, 2002, 99(11):3892-3904. [cited by applicant]
Gattinoni, L. et al., “Wnt signaling arrests effector T cell differentiation and generates CD8 [cited by applicant]
Gattinoni, L. et al., “A human memory T-cell subset with stem cell-like properties,” Nat. Med., 2011, 17(10):1290-1297. [cited by applicant]
Gattinoni, L. et al., “Paths to stemness: building the ultimate antitumour T cell,” Nat. Rev. Cancer, Oct. 2012, 12(10):671-684. [cited by applicant]
Gieffers, C. et al., “APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fcγ Receptors,” Mol. Cancer Therapeutics, Dec. 2013, 12(12):2735-2747. [cited by applicant]
Graham, F. L. et al., “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,” Virology, 1973, 52:456-467. [cited by applicant]
Griesbeck, M. et al., “Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-a Production in Women,” The Journal of Immunology, 2015, 195:5327-5336. [cited by applicant]
Hackett, P. et al., “A Transposon and Transposase System for Human Application,” Molecular Therapy, Apr. 2010, 18(4):674-683. [cited by applicant]
Herreros-Villanueva, M. et al., “Mouse models of pancreatic cancer,” World of Gastroenterol, Mar. 28, 2012, 18(12):1286-1294. [cited by applicant]
Jaeger, H. et al., “Physics of the Granular State,” Science, Mar. 20, 1992, 255:1523-1531. [cited by applicant]
Kandoth, C. et al., “Integrated genomic characterization of endometrial carcinoma,” Nature, May 2, 2013, 497(7447):67-73. [cited by applicant]
Khvorova et al., “The chemical evolution of oligonucleotide therapies of clinical utility,” Nat. Biotechnol., Mar. 2017, 35(3):238-248. [cited by applicant]
Kim, S., “Animal Models of Cancer in the Head and Neck Region,” Clinical and Experimental Otorhinolaryngology, Jun. 2009, 2(2):55-60. [cited by applicant]
Lee, D. et al., “4-1BB Signaling Activates the T Cell Factor 1 Effector/b-Catenin Pathway with Delayed Kinetics via ERK Signaling and Delayed PI3K/AKT Activation to Promote the Proliferation of CD8 [cited by applicant]
Levine, B. et al., “Gene transfer in humans using a conditionally replicating lentiviral vector,” PNAS, Nov. 14, 2006, 103(46):17372-17377. [cited by applicant]